Published in Vaccine Weekly, February 19th, 2003
The concern centers around the vaccine's effectiveness: Its manufacturers believe it could be beneficial even if it works for only one out of three who take it. Critics say that that's not nearly good enough, and may not be good at all.
VaxGen, Inc. has promised to release results of a last 5,400-person trial of its vaccine, known as AIDSVAX, before the end of March.
In recent weeks and months, short-sellers have taken control...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.